The FDA’s peptide ban is getting a second look under RFK Jr.

The peptide world got a jolt on February 27 when HHS Secretary RFK Jr. announced on the Joe Rogan Experience podcast that roughly 14 of the 19 peptides banned from compounding pharmacies in 2023 could return to legal status within weeks, though he didn’t specify which 14 compounds he plans to reinstate.

Compounds like BPC-157 and Thymosin Alpha-1—popular in anti-aging and recovery circles—were pulled from licensed pharmacies under the Biden-era FDA, a decision RFK Jr. is now looking to reverse.

His argument: the ban was about unproven efficacy, not safety. The FDA’s own records tell a more complicated story.

But here’s the catch

A substance can be safe for most people to take and not be an effective treatment for the disease in question,” says Dr. Gillian Goddard, a New York-based endocrinologist and adjunct professor at NYU Grossman School of Medicine. “To date, there is little data on the peptides in question in people. Most studies are in rats or even C. elegans worms.” The FDA’s own documentation flagged adverse events linked to at least one of the banned compounds, and noted little to no human data for many others.

There’s also the question of what “legal to compound” actually means in practice. Compounding pharmacies are regulated by state pharmacy boards, not the FDA, meaning standards vary widely, with no consistent batch-to-batch quality controls around potency or purity. That’s meaningfully different from a standard prescription drug on a pharmacy shelf.

The 2023 ban also had an unintended consequence: it pushed many users toward completely unregulated gray-market sources. With no pharmaceutical control or oversight, there’s no way to verify what’s actually in the product. “It could contain almost anything,” Dr. Goddard says. “No one is testing it to know.”

That’s precisely the problem RFK Jr. says he’s trying to fix. “My hope is that they’re going to get moved to a place where people have access to ethical suppliers,” he told Rogan, acknowledging, in the same breath, that the evidence supporting their use hasn’t been fully gathered.

As of now, no formal FDA rule has been issued. RFK Jr.’s announcement was made on a podcast, not through regulatory channels—meaning the timeline and scope are still fluid.

While access might change, the science and evidence don’t follow automatically.